STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more.
← Back to stories
2 articles from 1 source across the spectrum· Updated 7d ago
1 across the spectrum · tap a section to jump
Left
0 viewpointsNo Left coverage yet.
A blind spot on this side of the story.
Center
1 viewpointRight
0 viewpointsNo Right coverage yet.
A blind spot on this side of the story.